Stock SRX SIRTEX MEDICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Sirtex Medical Limited

Equities

SRX

AU000000SRX1

End-of-day quote Australian S.E.
Other stock markets
 		5-day change 1st Jan Change
- AUD -.--% Intraday chart for Sirtex Medical Limited +2.16% +103.09%
Apr. 15 Sierra Rutile Tells Shareholders to Reject PRM Services' Takover Bid MT
Apr. 12 Euroz Hartleys Adjusts Sierra Rutile Holdings’ Price Target to AU$0.15 From AU$0.12, Keeps at Speculative Buy MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Morgans rates SRX as Add
AQ
ASX-listed Sierra Rutile reports reduced production at Sierra Leone operations
AQ
Magle Chemoswed : enters collaboration with Sirtex Medical
AQ
Sirtex Medical : reaches milestone 100,000th patient dose delivery of SIR-Spheres® Y-90 resin microspheres
PU
Sirtex Medical : New Analysis Reveals First-Line Treatment Data on SIR-Spheres® Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
PU
Sirtex Medical : FOXFIRE Combined Analysis Results in First-Line Treatment of Metastatic Colorectal Cancer Presented at ASCO
PU
Sirtex Medical : SIR-Spheres® Y-90 Resin Microspheres Showed no Significant Difference in Overall Survival (OS) Compared to Sorafenib in Advanced HCC with Significantly Fewer Severe Adverse Events, New Asia-Pacific Study Finds
PU
Sirtex Medical : American Society of Clinical Oncology (ASCO) publishes abstract of SIRveNIB, an Investigator-led Asia Pacific Primary Liver Cancer Study to be presented at ASCO Annual Meeting in Chicago, 4 June 2017
PU
Sirtex Medical Inc. : Provides Update on SIR-Spheres® Y-90 Resin Microspheres in Combination with First-Line Chemotherapy for Patients with Unresectable Metastatic Colorectal Cancer (mCRC)
BU
Sirtex Medical : SIR-Spheres® Y-90 resin microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study against Standard Treatment Shows
PU
Sirtex Medical : NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer
PU
Sirtex Medical : NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin microspheres for the Treatment of Metastatic Colorectal Cancer
BU
Sirtex Medical : Liver Cancer Researchers from AP-HP and Singapore Collaborate on a Prospective Meta-Analysis of Two Studies of Y-90 resin microspheres versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma (HCC)
PU
Sirtex Medical Inc. : Announces 19 Percent Dose Sales Growth of SIR-Spheres® Y-90 resin microspheres in Fiscal Year 2016
BU
Sirtex Medical : Patients with Colorectal Cancer Liver Metastases Had Significantly Greater Depth of Tumour Response to SIR-Spheres® Y-90 resin microspheres, New SIRFLOX Analysis Shows
PU
Sirtex Medical : SIRveNIB, a Major Primary Liver Cancer Study in the Asia-Pacific Region, Completes Enrolment
PU
Sirtex Medical : Leading South African Health Insurer Approves Reimbursement of SIR-Spheres® Y-90 resin microspheres
PU
Sirtex Medical : Netherlands Healthcare Institute Approves Reimbursement of Selective Internal Radiation Therapy (SIRT)
PU
Sirtex Medical : Half-Year Dose Sales Up 18.7 Percent as SIRFLOX Study Published in Premier Oncology Journal
BU
Sirtex Medical : CORRECTING and REPLACING Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres® Y-90 resin microspheres for Fiscal Year Ending June 30, 2015
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRX Stock
  4. News Sirtex Medical Limited
  5. Press Releases